# Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab

> **NCT02304484** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 770 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **BIOLOGICAL:** Evolocumab

## Key facts

- **NCT ID:** NCT02304484
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-24
- **Primary completion:** 2018-03-09
- **Final completion:** 2018-03-09
- **Target enrollment:** 770 (ACTUAL)
- **Last updated:** 2019-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02304484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02304484, "Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02304484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*